Pharmacological perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19.
Int J Antimicrob Agents
; 55(6): 105995, 2020 Jun.
Article
in English
| MEDLINE | ID: covidwho-164767
ABSTRACT
Coronavirus disease 2019 (COVID-19) caused by the previously unknown pathogen, severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) is now a global pandemic. There are no vaccines or specific treatments against this new virus; therefore, there is an urgent need to advance novel therapeutic interventions for COVID-19. Glycyrrhizin is a triterpene saponin with various biological functions and pharmacological effects. This brief article discusses the therapeutic potential of glycyrrhizin for the treatment of COVID-19 from the perspective of its pharmacological action, including binding angiotensin-converting enzyme II (ACE2), downregulating proinflammatory cytokines, inhibiting the accumulation of intracellular reactive oxygen species (ROS), inhibiting thrombin, inhibiting the hyperproduction of airway exudates, and inducing endogenous interferon.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Coronavirus Infections
/
Glycyrrhizic Acid
/
Betacoronavirus
/
Anti-Inflammatory Agents
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Int J Antimicrob Agents
Year:
2020
Document Type:
Article
Affiliation country:
J.ijantimicag.2020.105995
Similar
MEDLINE
...
LILACS
LIS